HK Inno.N Corp. (195940) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of HK Inno.N Corp. KRW 52,436, price KRW 38,850, upside +35.0%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch HK Inno.N Corp. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 27,527 KRW – 66,855 KRW · fair‑value band 35,101 KRW – 68,576 KRW · the 38,850 KRW price screens below the 52,436 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow HK Inno.N in your weekly email
Every Wednesday you see whether HK Inno.N is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
HK inno.N Corporation engages in the pharmaceutical business in South Korea.
Show more
HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer; and nutrition and intravenous nutrition. It also provides health and beverage products, such as hangover relief, ready to drink, health supplements and health functional foods, as well as active pharmaceutical ingredients. In addition, the company offers beauty products under the bewants, ScalpMed, and KLEDERMA RX brands. It also exports its products to Japan, Southeast Asia, Latin America, Europe, and the Middle East countries. The company has joint research and development agreement with Nextgen Bioscience for NXC680, a candidate compound for treatment of Idiopathic Pulmonary Fibrosis. HK inno.N Corporation was founded in 1984 and is headquartered in Cheongju-si, South Korea.
Stock analysis
HK Inno.N Corp. (195940) currently trades at 38,850 KRW, while our model-based Fair Value estimate is 52,436 KRW, implying the stock looks roughly 25.9% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 57,957 KRW per share, and 17 of the 24 models we run sit above the 38,850 KRW price.
Bear case: the Economic Profit group reads lowest at 26,256 KRW, and 7 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 35,101 KRW (bear) to 68,576 KRW (bull), the price of 38,850 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
HK Inno.N Corp. reported revenue of 1.1T KRW in FY2025 versus 770B KRW in FY2021, a compound +8.4%/yr. Reported net income was 75.7B KRW in FY2025, compounding +32.3%/yr from FY2021.
Key figures
Market cap 1.1T KRW (≈ $770M) · P/S ratio 1.26 · Dividend yield 1.1% · Net margin 7.1% · Return on equity 3.9% · Return on assets (EBIT) 3.7% · Operating margin 11.2% · Revenue (TTM) 840B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).
What moves the price
The share trades about 32% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 35%, 195940 screens cheaper than that median.
Fair Value models
Bear 35,101 KRWFair Value 52,436 KRWBull 68,576 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+18.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.9%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+26.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+25.7%
Dividend (yield on the price)1.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 10%
2025 sits 60% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +9.3% a year for the price and +4.5% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside+35% · Top 25%
Profitability
Return on equity (TTM)4% · Below median
Return on assets2% · Below median
Net margin (TTM)5% · Below median
Operating margin (TTM)11% · Above median
Growth and dividend
Revenue growth5% · Above median
Dividend yield (TTM)1.1% · Below median
Balance sheet
Debt / equity0.11× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is HK Inno.N Corp. (195940) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 52,436 KRW versus a price of 38,850 KRW, about +35% upside (undervalued).
What is the fair value of 195940?
Our model-based fair value for HK Inno.N Corp. is 52,436 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 38,850 KRW.
What is the quality score of 195940?
HK Inno.N Corp. has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HK Inno.N Corp. (195940)?
Our model-based price target is the fair value of 52,436 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 35,101 KRW, optimistic scenario 68,576 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the HK Inno.N Corp. stock forecast for 2026?
Our models put fair value at 52,436 KRW, about +35% upside versus a price of 38,850 KRW (undervalued). Cautious scenario 35,101 KRW, optimistic scenario 68,576 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of HK Inno.N Corp. (195940)?
HK Inno.N Corp. reported trailing-twelve-month revenue of about 840B KRW (latest available figure, as of Sep 24, 2026).
Does HK Inno.N Corp. pay a dividend?
HK Inno.N Corp. currently shows a dividend yield of about 1.06% relative to its recent price (as of Sep 24, 2026).
What growth is priced into HK Inno.N Corp. (195940)?
For today's price to be fair in a discounted-cash-flow model, HK Inno.N Corp. would have to grow free cash flow by +11.5 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 195940 use?
Our models discount HK Inno.N Corp. at 10.3 %: a base by market capitalisation (small), damped by beta 0.53, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HK Inno.N Corp. that is +11.5 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has HK Inno.N Corp. (195940) delivered so far?
Over the past 5 years revenue at HK Inno.N Corp. grew +12.2 % a year. The price currently implies +11.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HK Inno.N Corp. (195940) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into HK Inno.N Corp. (+11.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HK Inno.N Corp. (195940)?
The free-cash-flow yield on the price is 6.88 %: that much free cash flow HK Inno.N Corp. produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HK Inno.N Corp. (195940)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HK Inno.N Corp. it is 52,436 KRW per share (as of Sep 24, 2026), against a price of 38,850 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is HK Inno.N Corp. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 195940 trades below its calculated fair value: price 38,850 KRW, fair value 52,436 KRW, a gap of about +35% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 195940?
No. The price is what the market pays today (38,850 KRW); the fair value is what the company's own numbers justify (52,436 KRW). For HK Inno.N Corp. the two are 13,586 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is HK Inno.N Corp. worth?
The market values HK Inno.N Corp. at about 1.1T KRW (market capitalisation, as of Sep 24, 2026). Per share that is 38,850 KRW; our models calculate a fair value of 52,436 KRW per share.
What do the bullish and bearish scenarios say about 195940?
Our models span a range for HK Inno.N Corp.: cautious scenario 35,101 KRW, base 52,436 KRW, optimistic 68,576 KRW per share (as of Sep 24, 2026, price 38,850 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of HK Inno.N Corp. (195940)?
Balance-sheet figures for HK Inno.N Corp. (as of Sep 24, 2026): return on equity 3.9%, debt of 0.11 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 195940 from its 52-week high?
HK Inno.N Corp. trades at 38,850 KRW, about 32% below its 52-week high of 57,155 KRW and 11% above the low of 34,900 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 52,436 KRW is for.
Which stocks are comparable to HK Inno.N Corp.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HK Inno.N Corp. stock attractive at the current price?
The data as of Sep 24, 2026: price 38,850 KRW, calculated fair value 52,436 KRW (+35%), Quality Score 57/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 195940 calculated?
We run HK Inno.N Corp. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 52,436 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. HK Inno.N Corp. currently trades 35 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HK Inno.N Corp. (195940)?
The closing price on Sep 23, 2026 was 38,850 KRW. Our model-based fair value is 52,436 KRW, about +35% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HK Inno.N Corp. right now?
Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (35,101 KRW to 68,576 KRW) leaves room in how you read the outcome.
Key figures of HK Inno.N Corp.
How large is the market capitalisation of HK Inno.N Corp. (195940)?
The market capitalisation of HK Inno.N Corp. is 1.1T KRW (≈ $770M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HK Inno.N Corp. (195940)?
The price-to-sales ratio of HK Inno.N Corp. is 1.26 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of HK Inno.N Corp. (195940)?
The dividend yield of HK Inno.N Corp. is 1.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of HK Inno.N Corp. (195940)?
The net margin of HK Inno.N Corp. is 7.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HK Inno.N Corp. (195940)?
The return on equity (ROE) of HK Inno.N Corp. is 3.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HK Inno.N Corp. (195940)?
On an EBIT basis the return on assets of HK Inno.N Corp. is 3.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HK Inno.N Corp. (195940)?
The operating margin of HK Inno.N Corp. is 11.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HK Inno.N Corp. (195940)?
Revenue at HK Inno.N Corp. is growing +5.1% versus a year earlier (3y avg +7.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HK Inno.N Corp. (195940)?
Earnings per share at HK Inno.N Corp. are growing +68.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does HK Inno.N Corp. (195940) carry?
The net debt of HK Inno.N Corp. is 413B KRW (fiscal year 2025, ≈ 5.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch HK Inno.N Corp. in the live analysis
One click puts HK Inno.N Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
